All Stories

  1. Applying a genetic risk score model to enhance prediction of future multiple sclerosis diagnosis at first presentation with optic neuritis
  2. Interpretation of composite OCT/MRI findings: a clinical review of retinotopy
  3. Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
  4. Partial Parallelism Plots
  5. Exploring Vitreous Haze as a Potential Biomarker for Accelerated Glymphatic Outflow and Neurodegeneration in Multiple Sclerosis: A Cross-Sectional Study
  6. Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial
  7. Correction: NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies
  8. NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies
  9. Reply: Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation
  10. Peripherin is a biomarker of axonal damage in peripheral nervous system disease
  11. The Association of Alcohol Consumption with Glaucoma and Related Traits
  12. Differentiating glaucoma from chiasmal compression using optical coherence tomography: the macular naso-temporal ratio
  13. Remodeling of the neuromuscular junction in myasthenia gravis increases serum neurofilament heavy chain levels
  14. Application of diagnostic criteria for optic neuritis – Authors' reply
  15. Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort
  16. Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders
  17. Correction: UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
  18. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
  19. Applying a genetic risk score model to enhance prediction of future Multiple Sclerosis diagnosis at first presentation with optic neuritis: a cohort study in the UK Biobank
  20. A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage
  21. Diagnosis and classification of optic neuritis
  22. The Role of the Inner Nuclear Layer for Perception of Persisting Tiling Inside a Monocular Scotoma
  23. UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
  24. Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort
  25. Pattern ERGs suggest a possible retinal contribution to the visual acuity loss in acute optic neuritis
  26. The 2022 Lady Estelle Wolfson lectureship on neurofilaments
  27. The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis
  28. Automated detection of hyperreflective foci in the outer nuclear layer of the retina
  29. The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts
  30. The prevalence of internuclear ophthalmoparesis in a population-based cohort of individuals with multiple sclerosis
  31. Artificial intelligence enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction and stroke
  32. Interpretation of Longitudinal Changes of the Inner Nuclear Layer in MS
  33. Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain
  34. Sub-cellular level resolution of common genetic variation in the photoreceptor layer identifies continuum between rare disease and common variation
  35. Associations of Alcohol Consumption and Smoking With Disease Risk and Neurodegeneration in Individuals With Multiple Sclerosis in the United Kingdom
  36. AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK
  37. Neuro-Ophthalmic Implications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Related Infection and Vaccination
  38. Blood GFAP as an emerging biomarker in brain and spinal cord disorders
  39. Upregulated Retinal Neurofilament Expression in Experimental Optic Neuritis
  40. Clinical review of retinotopy
  41. Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study
  42. Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
  43. Dynamic volume‐rendered optical coherence tomography pupillometry
  44. Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox
  45. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
  46. Myelin-oligodendrocyte glycoprotein antibody-associated disease
  47. Update on Optic Neuritis: An International View
  48. APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies
  49. Re-evaluating diabetic papillopathy using optical coherence tomography and inner retinal sublayer analysis
  50. Seven day pre-analytical stability of serum and plasma neurofilament light chain
  51. Artificial intelligence extension of the OSCAR‐IB criteria
  52. Three “Red Lines” for Pattern Recognition-Based Differential Diagnosis Using Optical Coherence Tomography in Clinical Practice
  53. Investigation of associations between retinal microvascular parameters and albuminuria in UK Biobank: a cross-sectional case-control study
  54. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries
  55. Peripapillary Hyper-reflective Ovoid Mass-like Structure (PHOMS): An Optical Coherence Tomography Marker of Axoplasmic Stasis in the Optic Nerve Head
  56. A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
  57. Reply to “Peripapillary Hyper‐Reflective Ovoid Masslike Structures in Astronauts”
  58. Relationships between retinal layer thickness and brain volumes in the UK Biobank cohort
  59. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
  60. Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain network
  61. Optical Coherence Tomography Angiography (OCTA) in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
  62. Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease
  63. Retinal asymmetry in multiple sclerosis
  64. Optical coherence tomography (OCT) in neuro-ophthalmology
  65. Serum neurofilament light chain withstands delayed freezing and repeated thawing
  66. Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis
  67. Comment on: Morphologic Features of Buried Optic Disc Drusen on En Face Optical Coherence Tomography and Optical Coherence Tomography Angiography
  68. Young Adults With Anterior Ischemic Optic Neuropathy: A Multicenter Optic Disc Drusen Study
  69. Multirater Validation of Peripapillary Hyperreflective Ovoid Mass-like Structures (PHOMS)
  70. Acute Disseminated Encephalomyelitis with Seizures and Myocarditis: A Fatal Triad
  71. Automated Pupillometry Using a Prototype Binocular Optical Coherence Tomography System
  72. Blocked Eye-Brain connection in Multiple Sclerosis
  73. Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank
  74. Biomarker Panel to Differentiate Brain Injury From Brain Dysfunction in Patients With Sepsis-Associated Encephalopathy
  75. Weighting evidence in MS: Obesity and neurodegeneration
  76. CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD
  77. Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives
  78. Genome-wide association meta-analysis of corneal curvature identifies novel loci and shared genetic influences across axial length and refractive error
  79. Anterior visual system imaging to investigate energy failure in multiple sclerosis
  80. Saccadic delay in multiple sclerosis: A quantitative description
  81. Can stability of visual fixation be a measure for disability in multiple sclerosis?
  82. Protein aggregate formation permits millennium-old brain preservation
  83. A conscious rethink: Why is brain tissue commonly preserved in the archaeological record? Commentary on: Petrone P, Pucci P, Niola M, et al. Heat-induced brain vitrification from the Vesuvius eruption in C.E. 79. N Engl J Med 2020;382:383-4. DOI: 10.10...
  84. Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort
  85. Associations with photoreceptor thickness measures in the UK Biobank
  86. Neuro-Ophthalmic Literature Review
  87. Multi-trait genome-wide association study identifies new loci associated with optic disc parameters
  88. Time is Vision
  89. Associations with Corneal Hysteresis in a Population Cohort
  90. A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients
  91. Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis
  92. Patterns of retrograde axonal degeneration in the visual system
  93. Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study
  94. Saccadic fatigability in the oculomotor system
  95. Progression of Anterograde Trans-Synaptic Degeneration in the Human Retina Is Modulated by Axonal Convergence and Divergence
  96. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up
  97. Diagnosing and quantifying a common deficit in multiple sclerosis
  98. Quantile regression analysis reveals widespread evidence for gene-environment or gene-gene interactions in myopia development
  99. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study
  100. Quantification of Visual Fixation in Multiple Sclerosis
  101. Correction: The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study
  102. A 30 s test for quantitative assessment of a relative afferent pupillary defect (RAPD): the infrared pupillary asymmetry (IPA)
  103. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
  104. The relevance of buffer system ionic strength in immunoassay development
  105. Cohort profile: design and methods in the eye and vision consortium of UK Biobank
  106. The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study
  107. An ontological foundation for ocular phenotypes and rare eye diseases
  108. Retinal Asymmetry in Multiple Sclerosis
  109. Peripapillary Hyperreflective Ovoid Mass-Like Structures
  110. The International Multiple Sclerosis Visual System Consortium
  111. Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline
  112. Peripapillary Ovoid Hyperreflectivity in Optic Disc Edema and Pseudopapilledema
  113. The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis
  114. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry
  115. Treating the Eyes to Help the Brain
  116. Neurofilaments as biomarkers in neurological disorders
  117. A standardized protocol for quantification of saccadic eye movements: DEMoNS
  118. Neuro-ophthalmic literature review
  119. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis
  120. Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error
  121. The Pulfrich phenomenon: Practical implications of the assessment of cases and effectiveness of treatment
  122. Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophy
  123. Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon
  124. Multicenter reliability of semiautomatic retinal layer segmentation using OCT
  125. Retinal optical coherence tomography shows optic disc changes in low intracranial pressure headaches: a case report
  126. Reply to the letter by Jasmin Zvorničanin on the article Prefoveal floaters as a differential diagnosis to optic neuritis: “mouches dormantes”
  127. Translational evidence for two distinct patterns of neuroaxonal injury in sepsis: a longitudinal, prospective translational study
  128. Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis
  129. The Optic Disc Drusen Studies Consortium Recommendations for Diagnosis of Optic Disc Drusen Using Optical Coherence Tomography
  130. Time is vision in recurrent optic neuritis
  131. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
  132. Biomarkers of Disease Progression
  133. Volume rendering of superficial optic disc drusen
  134. Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study
  135. Prefoveal floaters as a differential diagnosis to optic neuritis: “mouches dormantes”
  136. Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis
  137. Case 3-2017: A Man with Cardiac Sarcoidosis and New Diplopia and Weakness
  138. Optical coherence tomography angiography and retinal microvascular ramification in acute macular neuroretinopathy and paracentral acute middle maculopathy
  139. A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer
  140. Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
  141. Neuroprotection and visual function after optic neuritis
  142. Biomarkers in Neurodegenerative Diseases
  143. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis
  144. Retinal glymphatic system: an explanation for transient retinal layer volume changes?
  145. An early case of a natural barrier to axonal degeneration
  146. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study
  147. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies
  148. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study
  149. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study
  150. Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease
  151. Maintenance Intravenous Fluids in Acutely Ill Patients
  152. Autoimmunity in visual loss
  153. Elevated vitreous body glial fibrillary acidic protein in retinal diseases
  154. The prevalence of microcystic macular changes on optical coherence tomography of the macular region in optic nerve atrophy of non-neuritis origin: a prospective study
  155. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
  156. Cerebral Salt Wasting Syndrome
  157. Pain in Optic Perineuritis: Author Response
  158. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease
  159. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up
  160. Neuro-Ophthalmic Literature Review
  161. Diagnostic clues and manifesting carriers in fukutin-related protein (FKRP) limb-girdle muscular dystrophy
  162. The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid
  163. Visual pathway neurodegeneration winged by mitochondrial dysfunction
  164. Re: Garcia-Martin et al.: Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography (Ophthalmology 2014;121:573–9)
  165. Distribution of Retinal Layer Atrophy in Patients With Parkinson Disease and Association With Disease Severity and Duration
  166. Neuro-Ophthalmic Literature Review
  167. Physiological variation of retinal layer thickness is not caused by hydration: A randomised trial
  168. Retinal Segmentation to Demonstrate Hyperplasia in Ataxia of Charlevoix-Saguenay: Critique on Study Methodology and Results
  169. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
  170. The investigation of acute optic neuritis: a review and proposed protocol
  171. Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
  172. Serum lactate as a novel potential biomarker in multiple sclerosis
  173. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis
  174. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria
  175. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
  176. Neuro-Ophthalmic Literature Review
  177. Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis
  178. Diagnosis and classification of autoimmune optic neuropathy
  179. Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis
  180. Neurofilament heavy chain as a marker of neuroaxonal pathology and prognosis in acute encephalitis
  181. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
  182. Neuro-Ophthalmic Literature Review
  183. Recurrent Optic Perineuritis after Intranasal Cocaine Abuse
  184. Biomarker time out
  185. The Clinical Spectrum of Microcystic Macular Edema
  186. Distribution of Retinal Layer Atrophy in Patients With Parkinson Disease and Association With Disease Severity and Duration
  187. A dam for retrograde axonal degeneration in multiple sclerosis?
  188. Disease course heterogeneity and OCT in multiple sclerosis
  189. Retinal hyperaemia-related blood vessel artifacts are relevant to automated OCT layer segmentation
  190. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study
  191. Neurodegeneration and Multiple Sclerosis
  192. Optical Coherence Tomography to Assess Neurodegeneration in Multiple Sclerosis
  193. Optic Neuritis: Another Dickensian Diagnosis
  194. Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids and Fatal B-Cell Lymphoma—Reply
  195. Physiological variation of segmented OCT retinal layer thicknesses is short-lasting
  196. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
  197. Should CLIPPERS Be Considered a Prelymphoma State or a New Inflammatory Disease?—Reply
  198. Intrathecal oligoclonal IgG synthesis in multiple sclerosis
  199. Pain Management in Neurocritical Care
  200. Fatal B-cell Lymphoma Following Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids
  201. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis
  202. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome
  203. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported
  204. Influence of the Eye-Tracking–Based Follow-Up Function in Retinal Nerve Fiber Layer Thickness Using Fourier-Domain Optical Coherence Tomography
  205. Patterns of non-embolic transient monocular visual field loss
  206. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis
  207. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis
  208. Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?
  209. Embolic and Nonembolic Transient Monocular Visual Field Loss: A Clinicopathologic Review
  210. A Simple Sign for Recognizing Off–Axis OCT Measurement Beam Placement in the Context of Multicentre Studies
  211. Microcystic macular oedema in MS: T2 lesion or black hole?
  212. Comment on "Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model"
  213. Microcystic macular oedema confirmed, but not specific for multiple sclerosis
  214. Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1G93A Mice that Model ALS
  215. Recurrent Laughter-induced Syncope
  216. Biomarkers of Disease Progression
  217. Serum GFAP levels in optic neuropathies
  218. Glial S100B is elevated in serum across the spectrum of west nile virus infection
  219. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment
  220. Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury
  221. The Physiological Variation of the Retinal Nerve Fiber Layer Thickness and Macular Volume in Humans as Assessed by Spectral Domain–Optical Coherence Tomography
  222. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
  223. The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies
  224. Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest
  225. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis
  226. Axonal damage in the making: Neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter
  227. Cerebrospinal Fluid Ferritin Level, a Sensitive Diagnostic Test in Late-Presenting Subarachnoid Hemorrhage
  228. The Prognostic Value of Brain Extracellular Fluid Nitric Oxide Metabolites After Traumatic Brain Injury
  229. Erratum to: Rostrocaudal Dynamics of CSF Biomarkers
  230. Disease-Specific Cerebrospinal Fluid Investigations
  231. The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
  232. Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis
  233. Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure
  234. Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign
  235. Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus
  236. Exceptional preservation of a prehistoric human brain from Heslington, Yorkshire, UK
  237. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease
  238. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency
  239. The neurofilament light chain is not stable in vitro
  240. Reply
  241. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases
  242. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
  243. Remote Ischemic Preconditioning Protects the Brain Against Injury After Hypothermic Circulatory Arrest
  244. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament “hook” effect
  245. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study
  246. International Issues: The EAYNT
  247. Neurodegeneration in MS and NMO: The Eye and the Blood
  248. Matrix Metalloproteinases in Myasthenia Gravis
  249. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies
  250. Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
  251. Rostrocaudal Dynamics of CSF Biomarkers
  252. Evidence for acute neurotoxicity after chemotherapy
  253. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency
  254. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration
  255. PONM06 Plasma neurofilament heavy chain levels as a disease biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis
  256. Ocular Flutter Following Adenoviral Conjunctivitis in an Adult
  257. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis
  258. Anti-Heat Shock Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome
  259. Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases
  260. Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis
  261. Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes
  262. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels
  263. Liquordiagnostik bei CT-negativer Subarachnoidalblutung
  264. Cerebrospinal fluid ATP metabolites in multiple sclerosis
  265. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein
  266. Recurrent ptosis due to myopathy of the levator palpebrae superioris
  267. Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking
  268. Neurology training around the world: asking the trainees
  269. Neurofilament ELISA validation
  270. Short commentary on ‘a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking’
  271. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis
  272. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
  273. Synchronised Paroxysmal Ocular Tilt Reaction and Limb Dystonia
  274. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile Virus infection
  275. Synchronised Paroxysmal Ocular Tilt Reaction and Limb Dystonia
  276. A novel biomarker for retinal degeneration: vitreous body neurofilament proteins
  277. Cerebrospinal fluid biomarkers in multiple sclerosis
  278. The Longitudinal Profile of Bilirubin and Ferritin in the Cerebrospinal Fluid Following a Subarachnoid Hemorrhage: Diagnostic Implications
  279. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients
  280. The longitudinal profile of CSF markers during external lumbar drainage
  281. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome
  282. Improving the recovery of S100B protein in cerebral microdialysis: Implications for multimodal monitoring in neurocritical care
  283. EFNS guidelines on disease-specific CSF investigations
  284. The Value of the Serum Neurofilament Protein Heavy Chain as a Biomarker for Peri-operative Brain Injury After Carotid Endarterectomy
  285. Glial fibrillary acidic protein in Guillain-Barré syndrome: Methodological issues
  286. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
  287. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy
  288. The Historical Origin of the Pulfrich Effect: A Serendipitous Astronomic Observation at the Border of the Milky Way
  289. Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?
  290. Isolated, relapsing and progressive demyelinating diseases of the central nervous system
  291. Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology
  292. Glial and Axonal Body Fluid Biomarkers Are Related to Infarct Volume, Severity, and Outcome
  293. Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study
  294. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis
  295. Marathon related death due to brainstem herniation in rehydration-related hyponatraemia: a case report
  296. Assessing visual fields for driving in patients with paracentral scotomata
  297. CSF biomarkers for improved prognostic accuracy in acute CNS disease
  298. Plasma neurofilament heavy chain levels in Huntington's disease
  299. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis
  300. High CSF neurofilament heavy chain levels in neuromyelitis optica
  301. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain
  302. CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls
  303. A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia
  304. H<sub>2</sub>O Coma
  305. Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients
  306. CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndrome
  307. Brain Extracellular Fluid Nitrite/Nitrate Levels after Traumatic Brain Injury are Related to Survival
  308. Early Identification of Secondary Brain Damage in Subarachnoid Hemorrhage: A Role for Glial Fibrillary Acidic Protein
  309. Axonal damage and outcome in subarachnoid haemorrhage
  310. The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
  311. Clinical disorders affecting mesopic vision
  312. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis
  313. Intra-arterial papaverine used to treat cerebral vasospasm reduces brain oxygen
  314. Axonal damage markers in cerebrospinal fluid are increased in ALS
  315. Measurement of high affinity antibodies on antigen-immunoblots
  316. High Intracranial Pressure, Brain Herniation and Death in Cerebral Venous Thrombosis
  317. Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes
  318. Free phenytoin concentration measurement in brain extracellular fluid: a pilot study
  319. The Neurofilament Heavy Chain (NfH<sup>SMI35</sup>) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease
  320. Educational Approach on Stroke Training in Europe
  321. Spectrophotometry for Cerebrospinal Fluid Pigment Analysis
  322. Extracellular N‐acetylaspartate depletion in traumatic brain injury
  323. Amniotic fluid brain‐specific proteins are biomarkers for spinal cord injury in experimental myelomeningocele
  324. 4-Dihydromethyltrisporate dehydrogenase, an enzyme of the sex hormone pathway in Mucor mucedo, is constitutively transcribed but its activity is differently regulated in (+) and (−) mating types
  325. Optic flow induced nystagmus
  326. No evidence for MSRV viraemia and glial cell death in acute optic neuritis
  327. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
  328. Critical Illness Brain Syndrome (CIBS): An Underestimated Entity?
  329. Why Human Color Vision Cannot Reliably Detect Cerebrospinal Fluid Xanthochromia
  330. Extracellular fluid S100B in the injured brain: a future surrogate marker of acute brain injury?
  331. The Bryan cervical disc prosthesis as an alternative to arthrodesis in the treatment of cervical spondylosis: 46 CONSECUTIVE CASES
  332. Decreased CSF hypocretin-1 (orexin-A) after acute haemorrhagic brain injury
  333. Axonal Pathology in Subarachnoid and Intracerebral Hemorrhage
  334. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
  335. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis
  336. Central and Paracentral Visual Field Defects and Driving Abilities
  337. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis
  338. Spectrophotometry for Xanthochromia
  339. Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
  340. Axonal degeneration and inflammation in acute optic neuritis
  341. Transient monocular blindness: the controversial role of the ophthalmic artery
  342. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis
  343. Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage
  344. An ELISA for glial fibrillary acidic protein
  345. Temporal Alterations in Cerebrospinal Fluid Amyloid  -Protein and Apolipoprotein E After Subarachnoid Hemorrhage
  346. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage
  347. Alterations in Cerebrospinal Fluid Apolipoprotein E and Amyloid β -Protein after Traumatic Brain Injury
  348. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission
  349. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern
  350. A specific ELISA for measuring neurofilament heavy chain phosphoforms
  351. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
  352. Cerebrospinal fluid nitrite/nitrate predicts poor outcome in patients with subarachnoid hemorrhage (SAH)
  353. Quantification of neurodegeneration by measurement of brain-specific proteins
  354. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors
  355. Video Reconstruction of Vasospastic Transient Monocular Blindness
  356. Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury
  357. Cerebrospinal Fluid Apolipoprotein E Concentration Decreases after Traumatic Brain Injury
  358. Decreased Cerebrospinal Fluid Apolipoprotein E After Subarachnoid Hemorrhage: Correlation With Injury Severity and Clinical Outcome
  359. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy
  360. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease
  361. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: A pilot study
  362. Media Watch
  363. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations
  364. Rapidly developing intimal fibrosis mimicking giant cell arteritis
  365. Dense Kayser-Fleischer ring in asymptomatic Wilson's disease (hepatolenticular degeneration)
  366. Relapsing intracranial Rosai-Dorfman disease
  367. Recurrent ptosis
  368. Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat
  369. Recurrent ptosis in an adult due to isolated paresis of the levator palpebrae superioris and M�ller?s muscle of unknown aetiology
  370. Repetitive cerebral bleeding in an adult with Klippel-Trénaunay Syndrome
  371. Failure to detect bitemporal field defects due to chiasmal compression on a screening perimetry protocol
  372. Reply
  373. Hue memory and discrimination in young children
  374. Biological Markers
  375. Neuronal Cell Death and Axonal Degeneration: Neurofilaments as Biomarkers